SpringWorks Therapeutics Inc. announced that long-term efficacy and safety data from its Phase 3 DeFi trial of OGSIVEO (nirogacestat) for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE